Lidoflazine

This classification denotes a calcium channel blocker with the molecular formula C30H35F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4ZHN3HBTE, chemically known as 4-(4,4-bis(p-fluorophenyl)butyl)-1-piperazineaceto-2,6-xylidide but generally known as lidoflazine, which bears US NIH Compound Identifier 3926. European Medicines Agency schedules Lidoflazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08509MIG. The term LIDOFLAZINE is an International Non-Proprietary Name. World Health Organization schedules lidoflazine in its Anatomical Therapeutic Chemical (ATC) Classification. LIDOFLAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lidoflazine under HS 29335995 and SITC 51576. As of Q4 2014, LIDOFLAZINE remains the US FDA Preferred Term for this commodity. Lidoflazine bears US NLM identifiers UMLS ID C0023665 and NCI Concept Code C81685. SMILES: Fc1ccc(C(CCCN2CCN(CC2)CC(=O)Nc2c(cccc2C)C)c2ccc(F)cc2)cc1.